Skip to main content
SpringerLink
Log in

Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment

  • Chapter
Colorectal Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 811 Accesses

Abstract

Angiogenesis is an essential step in the growth and metastases of many solid tumors,including colorectal cancer (CRC). Efforts to inhibit angiogenesis as a potential antineoplastic strategy began more than 30 yr ago, and numerous angiogenic growth factors have subsequently been identified in large bowel tumors. The most successful antiangiogenic strategy to date has focused on inhibiting vascular endothelial growth factor (VEGF).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65–71.

    PubMed  CAS  Google Scholar 

  2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.

    Article  PubMed  CAS  Google Scholar 

  3. Takebayashi Y, Aklyama S, Yamada K, et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996;78:226–231.

    Article  PubMed  CAS  Google Scholar 

  4. Vermeulen PB, van den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316–322.

    PubMed  CAS  Google Scholar 

  5. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis [comment]. Cell 1994;79:185–188.

    Article  PubMed  CAS  Google Scholar 

  6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.

    Article  PubMed  CAS  Google Scholar 

  7. Wray CJ, Rilo HL, Ahmad SA. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 2004;13:631–641.

    Article  PubMed  CAS  Google Scholar 

  8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.

    Article  PubMed  CAS  Google Scholar 

  9. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [see comment]. Biochem Biophys Res Commun 2005;333:328–335.

    Article  PubMed  CAS  Google Scholar 

  10. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987–989.

    Article  PubMed  CAS  Google Scholar 

  11. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [see comment][erratum appears in Nat Med 2004;10(6):649]. Nat Med 2004;10:145–147.

    Article  PubMed  CAS  Google Scholar 

  12. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851–856.

    PubMed  CAS  Google Scholar 

  13. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843–850.

    PubMed  CAS  Google Scholar 

  14. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–65.

    Article  PubMed  CAS  Google Scholar 

  15. Giantonio BJ, Levy D, O′Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): updated results from the Eastern Cooperative Oncology Group (ECOG) study E2200. ASCO Gastrointestinal Symposium, abstract 289, 2004, p184.

    Google Scholar 

  16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]. N Engl J Med 2004;350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  17. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697–3705.

    Article  PubMed  CAS  Google Scholar 

  18. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer [see comment]. J Clin Oncol 2005;23:3706–3712.

    Article  PubMed  CAS  Google Scholar 

  19. Hochster H, Welles L, Hart L, et al. Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 & 2 Studies. Proc Am Soc Clin Oncol, abstract 3515, 2005, p2495.

    Google Scholar 

  20. Hochster H, Welles L, Hart L, et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial. ASCO Gastrointestinal Symposium, abstract 241, 2005, p204.

    Google Scholar 

  21. Giantonio BJ, Catalano NJM, O′Dwyer PJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol, abstract #2, 2005, p15.

    Google Scholar 

  22. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.

    Article  PubMed  CAS  Google Scholar 

  23. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/ irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol, abstract 3508, 2005, p2485.

    Google Scholar 

  24. Chen HX, Mooney M, Boron M, et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: an NCI treatment referral center trial (TRC-0301). Proc Am Soc Clin Oncol, abstract 3515, 2004, p249.

    Google Scholar 

  25. O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295–300.

    PubMed  CAS  Google Scholar 

  26. Dencausse Y, Hartung G, Sturm J, et al. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin [see comment]. Onkologie 2002;25:426–430.

    Article  PubMed  CAS  Google Scholar 

  27. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14 suppl 2:13–16.

    Google Scholar 

  28. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–657; discussion 657–658.

    Article  PubMed  Google Scholar 

  29. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–1061; discussion 1061–1064.

    Article  PubMed  Google Scholar 

  30. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver [see comment]. Br J Surg 2003;90:963–969.

    Article  PubMed  CAS  Google Scholar 

  31. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.

    Article  PubMed  CAS  Google Scholar 

  32. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation [see comment]. J Surg Res 2001;96:173–182.

    Article  PubMed  CAS  Google Scholar 

  33. Zhang F, Lei MP, Oswald TM, et al. The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds. Br J Plast Surg 2003;56:334–341.

    Article  PubMed  CAS  Google Scholar 

  34. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43–47.

    Article  PubMed  CAS  Google Scholar 

  35. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab, Proc Am Soc Clin Oncol, abstract 3702, 2004, p295.

    Google Scholar 

  36. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23:4853–4855.

    Article  PubMed  CAS  Google Scholar 

  37. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol, abstract 3, 2005, p25.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hermatology and Medical Oncology, Department of Medicine, Oregon Health and Science Iniversity Cancer Institute, Portland, OR

    John M. Strother MD & Charles D. Blanke MD, FACP

Authors
  1. John M. Strother MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles D. Blanke MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

    Leonard B. Saltz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Strother, J.M., Blanke, C.D. (2007). Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment. In: Markman, M., Saltz, L.B. (eds) Colorectal Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-215-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-215-1_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-751-8

  • Online ISBN: 978-1-59745-215-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation